Acta Med. 2012, 55: 153-159

https://doi.org/10.14712/18059694.2015.39

Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer

Adam Paulík, Jiří Grim, Stanislav Filip

Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Czech Republic: Department of Oncology and Radiotherapy

Received February 13, 2012
Accepted November 3, 2012

Crossref Cited-by Linking

  • Choi You-Ock, Jo Eun-Ah, Lee So-Hee, Park Ae-Ryoung, Yoon Jeong-Yi, Kang Jin-Suk: Evaluation of the Effectiveness of Atropine Administration for Prevention of Acute Cholinergic Syndrome Associated with Irinotecan. J. Korean Soc. Health-Syst. Pharm. 2022, 39, 174. <https://doi.org/10.32429/jkshp.2022.39.2.003>
  • Bechtold Baron, Clarke John: Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy. Expert Opinion on Drug Metabolism & Toxicology 2021, 17, 397. <https://doi.org/10.1080/17425255.2021.1867105>
  • Borah Gaurab, Bharali Manuj Kumar: Green tea catechins in combination with irinotecan attenuates tumorigenesis and treatment-associated toxicity in an inflammation-associated colon cancer mice model. J Egypt Natl Canc Inst 2021, 33. <https://doi.org/10.1186/s43046-021-00074-4>
  • ISHIMINE MOMOKO, YOKOMIZO TAKEHIKO, LEE-OKADA HYEON-CHEOL: Carboxylesterase 2: A Key Enzyme in Drug and Prodrug Metabolism. Juntendo Medical Journal 2020, 66, 120. <https://doi.org/10.14789/jmj.2020.66.JMJ19-R18>
  • Simões Ana Rita, Fernández-Rozadilla Ceres, Maroñas Olalla, Carracedo Ángel: The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?. JPM 2020, 10, 237. <https://doi.org/10.3390/jpm10040237>
  • Mukherji Deborah, Massih Sarah Abdel, Tfayli Arafat, Kanso Mariam, Faraj Walid: Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report. J Med Case Reports 2019, 13. <https://doi.org/10.1186/s13256-019-2013-z>
  • Fan Yingfang, Mansoor Najia, Ahmad Tasneem, Wu Zhuo X., Khan Rafeeq A., Czejka Martin, Sharib Syed, Ahmed Mansoor, Chen Zhe S., Yang Dong H.: Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK. PRA 2019, 14, 177. <https://doi.org/10.2174/1574892814666190212164356>
  • Buck Emanuel, Sprick Martin, Gaida Matthias, Gr�llich Carsten, Weber Tim, Herpel Esther, Bruckner Thomas, Koschny Ronald: Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. Oncol Lett 2019. <https://doi.org/10.3892/ol.2019.10043>
  • Palmirotta Raffaele, Carella Claudia, Silvestris Erica, Cives Mauro, Stucci Stefania Luigia, Tucci Marco, Lovero Domenica, Silvestris Franco: SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget 2018, 9, 25355. <https://doi.org/10.18632/oncotarget.25256>
  • Sanchez‑Dominguez Celia, Gallardo‑Blanco Hugo, Salinas‑Santander Mauricio, Ortiz‑Lopez Rocio: Uridine 5'‑diphospho‑glucronosyltrasferase: Its role in pharmacogenomics and human disease (Review). Exp Ther Med 2018. <https://doi.org/10.3892/etm.2018.6184>
  • Toshimoto Kota, Tomaru Atsuko, Hosokawa Masakiyo, Sugiyama Yuichi: Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects. Pharm Res 2017, 34, 1584. <https://doi.org/10.1007/s11095-017-2153-z>
  • Teft W A, Welch S, Lenehan J, Parfitt J, Choi Y-H, Winquist E, Kim R B: OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer 2015, 112, 857. <https://doi.org/10.1038/bjc.2015.5>
Crossref Cited-by Linking logo